Economic appraisal of Ontario's Universal Influenza Immunization Program: a cost-utility analysis.
BACKGROUND
In July 2000, the province of Ontario, Canada, initiated a universal influenza immunization program (UIIP) to provide free seasonal influenza vaccines for the entire population. This is the first large-scale program of its kind worldwide. The objective of this study was to conduct an economic appraisal of Ontario's UIIP compared to a targeted influenza immunization program (TIIP).


RESULTS
A cost-utility analysis using Ontario health administrative data was performed. The study was informed by a companion ecological study comparing physician visits, emergency department visits, hospitalizations, and deaths between 1997 and 2004 in Ontario and nine other Canadian provinces offering targeted immunization programs. The relative change estimates from pre-2000 to post-2000 as observed in other provinces were applied to pre-UIIP Ontario event rates to calculate the expected number of events had Ontario continued to offer targeted immunization. Main outcome measures were quality-adjusted life years (QALYs), costs in 2006 Canadian dollars, and incremental cost-utility ratios (incremental cost per QALY gained). Program and other costs were drawn from Ontario sources. Utility weights were obtained from the literature. The incremental cost of the program per QALY gained was calculated from the health care payer perspective. Ontario's UIIP costs approximately twice as much as a targeted program but reduces influenza cases by 61% and mortality by 28%, saving an estimated 1,134 QALYs per season overall. Reducing influenza cases decreases health care services cost by 52%. Most cost savings can be attributed to hospitalizations avoided. The incremental cost-effectiveness ratio is Can$10,797/QALY gained. Results are most sensitive to immunization cost and number of deaths averted.


CONCLUSIONS
Universal immunization against seasonal influenza was estimated to be an economically attractive intervention.
Sander
Beate
B
Department of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada. bsander@uhnres.utoronto.ca
Kwong
Jeffrey C
JC
Bauch
Chris T
CT
Maetzel
Andreas
A
McGeer
Allison
A
Raboud
Janet M
JM
Krahn
Murray
M
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002170:Canada; D002648:Child; D002675:Child, Preschool; D003362:Cost-Benefit Analysis / Q000379:methods*; D006801:Humans; D017589:Immunization Programs / Q000191:economics*; D007252:Influenza Vaccines / Q000191:economics* / Q000627:therapeutic use; D008875:Middle Aged; D009864:Ontario; D055815:Young Adult
D007252:Influenza Vaccines
Health Technol Assess. 2003;7(35):iii-iv, xi-xiii, 1-170
14609480
J Hosp Med. 2008 Mar;3(2):134-41
18438789
Rev Epidemiol Sante Publique. 2001 Apr;49(2):157-62
11319482
Can Commun Dis Rep. 2008 Jul;34(ACS-3):1-46
18802991
JAMA. 1994 Dec 7;272(21):1661-5
7966893
Pharmacoeconomics. 1999 Apr;15(4):369-76
10537955
Value Health. 2007 Mar-Apr;10(2):98-116
17391419
Vaccine. 2007 Aug 29;25(35):6511-21
17681651
Obstet Gynecol. 2006 Jun;107(6):1323-9
16738159
Vaccine. 2007 Apr 20;25(16):3233-9
17324489
Clin Drug Investig. 2004;24(7):395-407
17516726
Vaccine. 2006 Jun 5;24(23):4934-41
16678945
Ther Clin Risk Manag. 2006 Jun;2(2):219-26
18360596
Vaccine. 2006 Nov 17;24(47-48):6812-22
17034909
Cochrane Database Syst Rev. 2008 Apr 16;(2):CD004879
18425905
MMWR Recomm Rep. 2008 Aug 8;57(RR-7):1-60
18685555
Arch Pediatr Adolesc Med. 1995 Oct;149(10):1113-7
7550814
Am J Dis Child. 1991 Apr;145(4):445-8
1849344
Drugs. 2002;62(7):1013-24
11985488
Cancer. 2007 Jun 1;109(11):2357-64
17457827
Drugs Aging. 2000 Sep;17(3):217-27
11043820
Vaccine. 2006 May 8;24(19):4212-21
16546308
Vaccine. 2007 Jan 22;25(6):967-9
17052813
CMAJ. 1994 Mar 15;150(6):889-94
8131122
Vaccine. 2007 Sep 28;25(39-40):6900-10
17764790
Cochrane Database Syst Rev. 2006 Jul 19;(3):CD004876
16856068
Am J Prev Med. 2006 Jul;31(1):72-9
16777545
Respir Med. 2007 Jun;101(6):1244-50
17156991
Vaccine. 2007 Nov 19;25(47):8010-20
17936446
Vaccine. 2009 Apr 14;27(17):2350-5
19428850
Can Commun Dis Rep. 1993 Sep 15;19(17):136-42, 145-7
8220294
Kobe J Med Sci. 2006;52(3-4):97-109
16855372
Hum Vaccin. 2007 Jan-Feb;3(1):14-22
17245134
Cochrane Database Syst Rev. 2007 Apr 18;(2):CD001269
17443504
Vaccine. 2005 Mar 14;23(16):1973-80
15734070
Pediatr Infect Dis J. 2001 Aug;20(8):733-40
11734733
Health Aff (Millwood). 2008 Mar-Apr;27(2):w96-104
18216044
Vaccine. 2006 Feb 13;24(7):1035-43
16183177
Am J Prev Med. 2007 Feb;32(2):107-15
17234485
Am J Med. 2005 Jan;118(1):68-77
15639212
Pharm World Sci. 2008 Jan;30(1):39-43
17602309
Can Commun Dis Rep. 2000 Sep 1;26(17):141-8
11008402
PLoS Med. 2008 Oct 28;5(10):e211
18959473
Vaccine. 2006 Jan 30;24(5):629-35
16157429
J Occup Health. 2006 Jan;48(1):1-10
16484757
Arch Intern Med. 2006 Nov 13;166(20):2217-21
17101939
CMAJ. 1994 Apr 15;150(8):1255-61
8162548
Vaccine. 2008 Apr 16;26(17):2142-53
18343537